FindTrial
Sign In

A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease

A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000626
Enrollment
Unknown
Registered
2005-09-05
Start date
2004-10-07
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases

Interventions

Two groups:Curcumin and ginkgo extract 6 months versus placebo

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion: Possible or probable AD.

Exclusion criteria

Exclusion criteria: Exclusion: Anticoagulant or antiplatelet treatment or bleeding risk factors; currently smoking; or other severe illness.

Design outcomes

Primary

MeasureTime frame
Setting up formulation, patient recruitment, and assay procedures at 0, 1, and 6 months, in preparation for a later clinical trial testing the effectiveness of curcumin and ginkgo in slowing AD progression.;—

Secondary

MeasureTime frame
Change in biochemical measures of AD: Plasma isoprostane and A-beta levels at 1 and 6 months.;Change in cognitive measures of AD: MMSE at 6 months.;Change in others: cholesterol, lipid, C reactive protein, and metal levels in serum at 1 and 6 months.;Curcumin and metabolites at 1 month.;—

Countries

China

Contacts

Public ContactLarry Baum
lwbaum@cuhk.edu.hk+852 26323146

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026